Przyklenk Karin, Maynard Michelle, Darling Chad E, Whittaker Peter
Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, 01655, USA.
J Pharmacol Exp Ther. 2005 Sep;314(3):1386-92. doi: 10.1124/jpet.105.087742. Epub 2005 May 26.
Pretreatment with D-myo-inositol-1,4,5-trisphosphate hexasodium (D-myo-IP(3)), the sodium salt of the second messenger inositol 1,4,5-trisphosphate (IP(3)), is cardioprotective and triggers a reduction of infarct size comparable in magnitude to that obtained with ischemic preconditioning. However, this observation is enigmatic; whereas IP(3) signaling is conventionally initiated by receptor binding, IP(3) receptors are typically considered to be intracellular, and D-myo-IP(3) is membrane-impermeable. We propose that this paradox is explained by the presence of poorly characterized external IP(3) receptors and hypothesize that: 1) infarct size reduction with D-myo-IP(3) is receptor-mediated; and 2) communication via gap junctions and/or hemichannels is required to initiate this protection. To investigate the role of receptor binding, isolated buffer-perfused rabbit hearts underwent 30 min of coronary occlusion (CO) and 2 h of reflow. Prior to CO, hearts received no treatment (controls), D-myo-IP(3), L-myo-IP(3) (enantiomer not recognized by the IP(3) receptor), D-myo-IP(3) + the IP(3) receptor inhibitor xestospongin C (XeC), or XeC alone. Infarct size, assessed by tetrazolium staining, was reduced with D-myo-IP(3) treatment, whereas hearts that received L-myo-IP(3) or D-myo-IP(3) + XeC showed no protection. To evaluate the contribution of gap junctions/hemichannels, additional control and D-myo-IP(3)-treated cohorts received a 5-min infusion of heptanol or Gap 27, two structurally distinct gap junction inhibitors, administered at doses confirmed to attenuate intercellular transmission of a gap junction-permeable fluorescent dye. There was no infarct-sparing effect of D-myo-IP(3) in inhibitor-treated hearts. These data support the concepts that infarct size reduction with D-myo-IP(3) is triggered by receptor binding and that communication via gap junctions/hemichannels is involved in initiating this protection.
用D-肌醇-1,4,5-三磷酸六钠(D-myo-IP(3))进行预处理具有心脏保护作用,它是第二信使肌醇1,4,5-三磷酸(IP(3))的钠盐,能使梗死面积缩小,缩小幅度与缺血预处理相当。然而,这一现象令人费解;虽然IP(3)信号传统上是由受体结合启动的,但IP(3)受体通常被认为位于细胞内,而D-myo-IP(3)不能透过细胞膜。我们认为,这种矛盾可以通过存在特征不明的细胞外IP(3)受体来解释,并提出以下假设:1)D-myo-IP(3)使梗死面积缩小是由受体介导的;2)需要通过缝隙连接和/或半通道进行通讯来启动这种保护作用。为了研究受体结合的作用,对离体缓冲灌注兔心脏进行30分钟冠状动脉闭塞(CO)和2小时再灌注。在CO之前,心脏未接受任何处理(对照组)、D-myo-IP(3)、L-myo-IP(3)(IP(3)受体不识别的对映体)、D-myo-IP(3)+IP(3)受体抑制剂西司他汀C(XeC)或单独的XeC。通过四氮唑染色评估梗死面积,D-myo-IP(3)处理可使梗死面积缩小,而接受L-myo-IP(3)或D-myo-IP(3)+XeC的心脏未显示出保护作用。为了评估缝隙连接/半通道的作用,另外的对照组和接受D-myo-IP(3)处理的组接受了5分钟的庚醇或Gap 27输注,这两种结构不同的缝隙连接抑制剂的剂量经确认可减弱缝隙连接通透性荧光染料的细胞间传递。在接受抑制剂处理的心脏中,D-myo-IP(3)没有梗死挽救作用。这些数据支持以下观点:D-myo-IP(3)使梗死面积缩小是由受体结合触发的,并且通过缝隙连接/半通道进行的通讯参与了这种保护作用的启动。